1

 1. What comments or suggestions does the committee
have for improving the mathematical, statistical or
clinical concepts in the model?

2

 2. How does the committee envision such a model can be best
utilized to improve drug development?

3

 3. Does the committee have any general recommendations for further
exploratory research into drug disease models?
